NVO (NVO) Stock Price & Analysis
NVO (NVO) rose 2.85% to USD 42.19 as of June 9, 2026 at 23:44 UTC, according to Nexqual real-time market data.
NVO last closed at USD 41.02; the session ranged USD 41.08–42.31 on volume of 14,696,763 shares. Market capitalization is $186.86B, with a 52-week range of USD 35.12–81.44 (NYQ). Source: Nexqual, June 9, 2026 at 23:44 UTC.
Key Statistics (as of June 9, 2026 at 23:44 UTC)
| Price | USD 42.19 |
|---|---|
| Change | ▲ 2.85% (up) |
| Previous Close | USD 41.02 |
| Open | USD 41.08 |
| Day Range | USD 41.08 – 42.31 |
| 52-Week Range | USD 35.12 – 81.44 |
| Volume | 14,696,763 shares |
| Market Cap | $186.86B |
| Exchange | NYQ |
Technical Analysis (NVO)
Nexqual's technical model rates NVO "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 9, 2026 at 23:44 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 47.73 (neutral) |
| vs SMA50 | Above (USD 41.97) |
| MACD | -0.16 (negative) |
Analyst Ratings (NVO)
Wall Street analysts rate NVO "Buy" based on 12 analysts, with a mean price target of USD 46.96 (range USD 39.26–63.7), per Nexqual as of June 9, 2026 at 23:44 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 46.96 |
| High Target | USD 63.7 |
| Low Target | USD 39.26 |
| Buy / Hold / Sell | 5 / 9 / 0 |
Earnings (NVO)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 5.2 |
| Revenue Estimate | $72.07B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 6.63 vs est 6.96 ▼ miss |
| 2025-12-31 | USD 6.04 vs est 5.9 ▲ beat |
| 2025-09-30 | USD 4.5 vs est 4.24 ▲ beat |
| 2025-06-30 | USD 5.96 vs est 6 ▼ miss |
Source: Nexqual, June 9, 2026 at 23:44 UTC.
Financials & Fundamentals (NVO)
| Total Revenue | $327.80B |
|---|---|
| Revenue Growth (YoY) | +24.00% |
| Gross Margin | +83.20% |
| Operating Margin | +61.57% |
| Profit Margin | +37.21% |
| ROE | +71.40% |
| Debt / Equity | 72.09 |
| Current Ratio | 0.79 |
| Total Cash | $21.63B |
| Total Debt | $146.38B |
| Free Cash Flow | $-12.04B |
Source: Nexqual, June 9, 2026 at 23:44 UTC.
Financial Health Score (NVO)
Nexqual rates NVO's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:44 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 83%, operating 62% |
| Balance Sheet | Mixed — $21.6B cash vs $146.4B debt |
| Cash Flow | Weak — FCF negative: -$12.0B, burning cash |
| Efficiency | Strong — ROE 71%, ROA 19.2% |
Ownership (NVO)
| Insider Ownership | +0.01% |
|---|---|
| Institutional Ownership | +9.87% |
| Shares Outstanding | 3.35B |
| Float | 3.19B |
| Short % of Float | +0.71% |
Source: Nexqual, June 9, 2026 at 23:44 UTC.
Leadership (NVO)
NVO is led by Maziar Mike Doustdar B.A. (age 55), President, CEO & Member of the Management Board, per Nexqual as of June 9, 2026 at 23:44 UTC.
| President, CEO & Member of the Management Board | Maziar Mike Doustdar B.A. (age 55) |
|---|---|
| Executive VP, CFO & Member of the Management Board | Karsten Munk Knudsen (age 54) |
| EVP of R & D, Chief Scientific Officer and Member of the Management Board | Martin Holst Lange (age 55) |
Major Backers & Investors (NVO)
Notable institutional backers of NVO include Dodge & Cox Inc., LOOMIS SAYLES & CO L P, Franklin Resources, Inc., according to Nexqual as of June 9, 2026 at 23:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 1.02% |
| LOOMIS SAYLES & CO L P | 0.64% |
| Franklin Resources, Inc. | 0.47% |
| Price (T.Rowe) Associates Inc | 0.44% |
| Capital International Investors | 0.35% |
| Susquehanna International Group, LLP | 0.33% |
| Morgan Stanley | 0.32% |
| Bank of America Corporation | 0.32% |
Source: Nexqual, June 9, 2026 at 23:44 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LLY | Eli Lilly and Company | USD 1,144.68 | ▲ 1.17% |
| UNH | UnitedHealth Group Incorporated | USD 413 | ▲ 3.39% |
| ASML | ASML Holding N.V. - New York Re | USD 1,777.77 | ▲ 8.29% |
| SMCI | Super Micro Computer, Inc. | USD 40.64 | ▼ 2.4% |
| HIMS | Hims & Hers Health, Inc. | USD 28.98 | ▲ 10.65% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:44 UTC. This page is informational and not investment advice.